Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Phase 1B: Open label (all patients receive PEGPH20+gemcitabine), dose escalation, safety and
tolerability study to determine the safe dose of PEGPH20 to use in combination with
gemcitabine in Stage IV previously untreated pancreatic cancer patients.
Phase 2: Randomized, double blind study to compare the effect of overall survival of
gemcitabine plus PEGPH20 vs gemcitabine plus placebo in Stage IV previously untreated
pancreatic cancer patients.